تحميل
NASDAQHealthcareBiotechnology
أحدث البيانات المتاحة
259.86 US$
−3.69 US$ · -1.40%
Praxis Precision Medicines, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating innovative treatments for central nervous system (CNS) conditions that stem from an imbalance in neuronal activity. The company's primary investigational compounds currently undergoing evaluation include: PRAX-114, an extrasynaptic-preferring positive allosteric modulator of the GABAA receptor, which is currently in Phase IIa clinical trials for addressing both major depressive disorder and perimenopausal depression. Additionally, PRAX-944, a small molecule designed to selectively inhibit T-type calcium channels, is also progressing through Phase IIa clinical trials to manage essential tremor. Beyond these, Praxis is also advancing a pipeline of other promising drug candidates, such as: PRAX-562, a persistent sodium current blocker, undergoing Phase I clinical evaluation for treating severe pediatric epilepsy and adult cephalgia (headaches). PRAX-222, an antisense oligonucleotide (ASO) aimed at individuals suffering from gain-of-function (GOF) SCN2A epilepsy. And a program targeting KCNT1 for the treatment of KCNT1 GOF epilepsy. To further its research and development efforts, Praxis maintains several strategic alliances. These include a cooperation and licensing arrangement with RogCon Inc.; a licensing deal with Purdue Neuroscience Company; a comprehensive research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and a collaborative project with The Florey Institute focused on the creation of three new antisense oligonucleotides (ASOs). Established in 2015, the company's headquarters are situated in Boston, Massachusetts.
الإغلاق السابق
259.86 US$
−3.69 US$ · -1.40%
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
Praxis Precision Medicines, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating innovative treatments for central nervous system (CNS) conditions that stem from an imbalance in neuronal activity. The company's primary investigational compounds currently undergoing evaluation include: PRAX-114, an extrasynaptic-preferring positive allosteric modulator of the GABAA receptor, which is currently in Phase IIa clinical trials for addressing both major depressive disorder and perimenopausal depression. Additionally, PRAX-944, a small molecule designed to selectively inhibit T-type calcium channels, is also progressing through Phase IIa clinical trials to manage essential tremor. Beyond these, Praxis is also advancing a pipeline of other promising drug candidates, such as: PRAX-562, a persistent sodium current blocker, undergoing Phase I clinical evaluation for treating severe pediatric epilepsy and adult cephalgia (headaches). PRAX-222, an antisense oligonucleotide (ASO) aimed at individuals suffering from gain-of-function (GOF) SCN2A epilepsy. And a program targeting KCNT1 for the treatment of KCNT1 GOF epilepsy. To further its research and development efforts, Praxis maintains several strategic alliances. These include a cooperation and licensing arrangement with RogCon Inc.; a licensing deal with Purdue Neuroscience Company; a comprehensive research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and a collaborative project with The Florey Institute focused on the creation of three new antisense oligonucleotides (ASOs). Established in 2015, the company's headquarters are situated in Boston, Massachusetts.
نطاق اليوم
السعر الحالي 259.86 US$
نطاق 52 أسبوعًا
السعر الحالي 259.86 US$
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
نقاط GoAI
احتفاظ
تقييم
30
مرتفع السعر
المشاعر
75
صعودي
المخاطر
60
مخاطر أعلى من المعتاد
الزخم
68
زخم متزايد
بحث كامل عن GoAI
تابع للاطلاع على أدلة ومحفزات ومخاطر أعمق.
Praxis Precision Medicines, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating innovative treatments for central nervous system (CNS) conditions that stem from an imbalance in neuronal activity. The company's primary investigational compounds currently undergoing evaluation include: PRAX-114, an extrasynaptic-preferring positive allosteric modulator of the GABAA receptor, which is currently in Phase IIa clinical trials for addressing both major depressive disorder and perimenopausal depression. Additionally, PRAX-944, a small molecule designed to selectively inhibit T-type calcium channels, is also progressing through Phase IIa clinical trials to manage essential tremor. Beyond these, Praxis is also advancing a pipeline of other promising drug candidates, such as: PRAX-562, a persistent sodium current blocker, undergoing Phase I clinical evaluation for treating severe pediatric epilepsy and adult cephalgia (headaches). PRAX-222, an antisense oligonucleotide (ASO) aimed at individuals suffering from gain-of-function (GOF) SCN2A epilepsy. And a program targeting KCNT1 for the treatment of KCNT1 GOF epilepsy. To further its research and development efforts, Praxis maintains several strategic alliances. These include a cooperation and licensing arrangement with RogCon Inc.; a licensing deal with Purdue Neuroscience Company; a comprehensive research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and a collaborative project with The Florey Institute focused on the creation of three new antisense oligonucleotides (ASOs). Established in 2015, the company's headquarters are situated in Boston, Massachusetts.
نطاق اليوم
السعر الحالي 259.86 US$
نطاق 52 أسبوعًا
السعر الحالي 259.86 US$
الربحية كنسبة مئوية من الإيرادات المعلنة.
الإيرادات
الدخل التشغيلي
صافي الدخل
| البند (USD) | السنة المالية 2025 | السنة المالية 2024 | السنة المالية 2023 | السنة المالية 2022 | السنة المالية 2021 |
|---|---|---|---|---|---|
| الإيرادات | — | 8.55 مليون USD | 2.45 مليون USD | — | — |
| تكلفة البضاعة المباعة | 140 ألف USD | 152.41 مليون USD | 86.77 مليون USD | 154.44 مليون USD | — |
| الربح الإجمالي | −140 ألف USD | −143.86 مليون USD | −84.32 مليون USD | −154.44 مليون USD | — |
| البحث والتطوير | 267.12 مليون USD | 152.41 مليون USD | 86.77 مليون USD | 155.04 مليون USD | 120.26 مليون USD |
| مصاريف البيع والمصاريف العمومية والإدارية | 59.08 مليون USD | 56.31 مليون USD | 42.05 مليون USD | 59.55 مليون USD | 47.08 مليون USD |
| نفقات التشغيل | 326.06 مليون USD | 56.31 مليون USD | 42.05 مليون USD | 60.55 مليون USD | 167.33 مليون USD |
| دخل الفوائد | 22.93 مليون USD | 17.35 مليون USD | — | — | — |
| الاستهلاك والإطفاء | 140 ألف USD | 358 ألف USD | 432 ألف USD | 419 ألف USD | 182 ألف USD |
| الدخل التشغيلي | −326.2 مليون USD | −200.17 مليون USD | −126.37 مليون USD | −214.99 مليون USD | −167.33 مليون USD |
| صافي الدخل | −303.27 مليون USD | −182.82 مليون USD | −123.28 مليون USD | −214.03 مليون USD | −167.06 مليون USD |
تم تحديث حقائق الشركة 11 أكتوبر 2026.
أحدث النتائج المعلنة
أحدث النتائج المعلنة
قد تتغير تقديرات المحللين الخارجيين، وهي ليست توصيات من GoAI.
صناديق متداولة تفصح عن تعرضها لهذا السهم.
Vanguard Morningstar Total Stock Market ETFVTI310.79 مليون0.01%2.3 ترليون USD0.03%381.94 US$+0.63%
Vanguard Morningstar Small-Cap ETFVB224.73 مليون0.12%185.3 مليار USD0.03%289.48 US$+0.64%
iShares Russell 2000 ETFIWM174.37 مليون0.22%78.74 مليار USD0.19%278.94 US$+0.49%
Vanguard Morningstar Small-Cap Value ETFVBR134.33 مليون0.20%68.2 مليار USD0.05%234.43 US$+0.22%
State Street SPDR S&P Biotech ETFXBI114.3 مليون1.16%9.87 مليار USD0.35%153.77 US$+3.00%
Vanguard Extended Market ETFVXF106.66 مليون0.11%95.4 مليار USD0.05%235 US$+0.80%
iShares Russell 2000 Growth ETFIWO61.19 مليون0.44%13.92 مليار USD0.24%356.78 US$+0.94%
iShares Biotechnology ETFIBB53.63 مليون0.51%10.82 مليار USD0.44%206.49 US$+3.00%Vanguard Morningstar Total Stock Market ETFVTIVanguard Morningstar Small-Cap ETFVBiShares Russell 2000 ETFIWMVanguard Morningstar Small-Cap Value ETFVBRState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBالمحتوى المُنشأ بالذكاء الاصطناعي وبيانات السوق المتأخرة لأغراض معلوماتية وتعليمية فقط، ولا تُعد نصيحة استثمارية.
